A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis

Moore, Angela; Gordon, Kenneth B.; Kang, Sewon; Gottlieb, Alice B.; Freundlich, Bruce; Xia, H. Amy; Stevens, Seth R.

doi:10.1016/j.jaad.2006.09.002

Cited by 140 publications

(143 citation statements)

References 11 publications

(11 reference statements)

Supporting

Mentioning

133

Contrasting

Unclassified

Order By: Relevance

“…All large trials with > 500 patients investigated biological interventions. The primary outcome was PASI 75 response in 30 studies (62%), mean PASI change in 11 studies (23%), Investigator Global Assessment of clear or almost clear in four studies, [41][42][43]46 American College of Rheumatology-20 response in two studies, 52,58 PASI 50 response in two studies 33,44 and mean change in Psoriasis Scalp Severity Index in one study. 40 The primary end point was assessed between week 8 and week 24 in all trials included.…”

Section: Qualitative Resultsmentioning

confidence: 99%

Efficacy and safety of systemic treatments for moderate‐to‐severe psoriasis: meta‐analysis of randomized controlled trials

et al. 2014

View full text Add to dashboard Cite

Section: Qualitative Resultsmentioning

confidence: 99%

Efficacy and safety of systemic treatments for moderate‐to‐severe psoriasis: meta‐analysis of randomized controlled trials

et al. 2014

View full text Add to dashboard Cite

“…Efficacy analysis at week 24 showed a PGA~2 for 70% of the patients in the continuous group and a PGA~2 for 51% of the patients in the interrupted group. In the latter group, median time to relapse was 39.6 days and median time to regain responder status after retreatment was 35 days (18). Also, a paediatric long-term study performed by Paller et al was published in the New England Journal of Medicine to evaluate the efficacy and safety of etanercept throughout a 48-week study including 211 patients affected by psoriasis aged 4 to 17 years (19).…”

Section: Discussionmentioning

confidence: 99%

Continuous Treatment of Plaque-Type Psoriasis with Etanercept: An Observational Long-Term Experience

Esposito

Giunta

Mazzotta

et al. 2010

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

To assess the long-term efficacy and safety profile and the patient-reported outcomes (PRO) in patients with moderate-to-severe plaque-type psoriasis receiving continuous etanercept treatment. An open-label study was conducted to evaluate etanercept as long-term treatment for moderate-to-severe plaque psoriasis. Continuous therapy was administered at a dose of 50 mg subcutaneously twice weekly for 12 weeks followed by a continuous treatment with 50 mg subcutaneously once weekly or 25 mg twice weekly throughout a 96-week study. The primary measure of efficacy was the proportion of patients with PASI 75 at week 24, 48 and 96. Patient-reported outcomes (PRO) were also assessed during the study, at week 24, 48 and 96, including the Dermatology Life Quality Index (DLQI) and the Psoriasis Disability Index (PDI). At baseline, mean PASI score, DLQI and PDI for patients eligible to initiate treatment with etanercept showed significant disease severity, quality-of-Iife impairment and psoriasis-related disability. At week 96, patients showed statistically significant and meaningful improvements. The continuous etanercept regimen provided a consistent improvement in both clinical disease parameters and PRO measures.

show abstract

“…The duration of response following a single dose of adalimumab or infliximab is up to 3 months [32,33]. The terminal elimination half-life of etanercept is shorter (5 days) [30], but the duration of response can reach 3 months, suggesting a possible maintenance of the immune effect after terminal elimination [34]. The mean terminal elimination half-life of rituximab is 3 weeks, but the mean B cell lymphocyte depletion duration is 12 months [25,35].…”

Section: Methodsmentioning

confidence: 99%

Factors Associated with Severe Skin Infections in Patients Treated with Biologic Therapies for Inflammatory Rheumatic Diseases

Régnier‐Rosencher¹,

Farhi²,

Lebrun

et al. 2012

Dermatology

View full text Add to dashboard Cite

Background: The incidence of severe infections is increased under biologic therapies and the skin is the second localization. Objective: To appraise the factors associated with severe skin infections (SSI) in patients under biologic therapies for inflammatory rheumatic diseases (IRD). Methods: We performed a case-control (ratio 1:3) study nested in a prospective cohort of patients with IRD. SSI was defined as requiring hospitalization or intravenous anti-infectious therapy. We defined two imbedded periods: period A was the time window between the first biologic therapy and the SSI; period B was the last 3 or 12 months (for tumor necrosis factor blockers or rituximab, respectively) before the SSI. Results: Among 4,361 patients with IRD, 29 had a SSI under biologic therapy. In multivariate analyses, SSI were significantly associated with smoking, baseline C-reactive protein and gammaglobulinemia, non-steroidal anti-inflammatory drugs before biologic therapy, cumulative dose of steroids, concomitant steroids during period A, number of different biologic therapies during period A, treatment with infliximab during period A, period B or as first biologic therapy and treatment at high dose during period B. Conclusion: In patients under biologic therapies for IRD, the risk of SSI is associated with several factors including tobacco, treatment with infliximab or high dose range.

show abstract

A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis

Cited by 140 publications

References 11 publications

Efficacy and safety of systemic treatments for moderate‐to‐severe psoriasis: meta‐analysis of randomized controlled trials

Efficacy and safety of systemic treatments for moderate‐to‐severe psoriasis: meta‐analysis of randomized controlled trials

Continuous Treatment of Plaque-Type Psoriasis with Etanercept: An Observational Long-Term Experience

Factors Associated with Severe Skin Infections in Patients Treated with Biologic Therapies for Inflammatory Rheumatic Diseases

Contact Info

Product

Resources

About